Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | TPO | P07202 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10699801 | 0.86 | KDM4E (0.68) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL1958079 | 0.84 | KDM4E (0.54) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL1958856 | 0.79 | SMN1; SMN2 (0.46) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL1962737 | 0.72 | SMN1; SMN2 (0.41) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL10667165 | 0.70 | KDM4E (0.63) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL6673604 | 0.66 | EPHX2 (0.42) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL1958327 | 0.64 | MTNR1A (0.52) | KDM4EALDH1A1KMT2AMEN1GAA | |
| Formic Acid SCHEMBL6687413 | 0.63 | EPHX2 (0.40) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL7673685 | 0.62 | MEN1 (0.56) | KDM4EALDH1A1KMT2AMEN1GAA | |
| SCHEMBL1945331 | 0.62 | KDM4E (0.64) | KDM4EALDH1A1KMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236951-B2 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2012-08-07 | — | — | US | disclosed |
| EP-2332541-A1 | Use of thioxanthine derivatives as MPO inhibitors | AstraZeneca AB (SE) | 2011-06-15 | — | — | EP | disclosed |
| US-20080293748-A1 | Thioxanthine Derivatives as Myeloperoxidase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-7425560-B2 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2008-09-16 | — | — | US | disclosed |
| US-20050234036-A1 | Thioxanthine derivatives as myeloperoxidase inhibitors | ASTRAZENECA AB (SE) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293748-A1 | Thioxanthine Derivatives as Myeloperoxidase Inhibitors | MPO, XDH, EPX | KDM4E 3438/4885ALDH1A1 178/4885KMT2A 3549/4885 |
| US-20050234036-A1 | Thioxanthine derivatives as myeloperoxidase inhibitors | MPO, XDH, EPX | KDM4E 3438/4885ALDH1A1 178/4885KMT2A 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.